Medical disclaimer: This article is for general informational purposes only and does not constitute medical advice. Bariatric surgery is a major operative procedure requiring thorough individual assessment by qualified bariatric surgeons, physicians, dietitians, and psychologists. Always consult your treating team before making any decisions regarding surgery or pre-operative preparation.
Bariatric surgery consistently delivers the most durable long-term weight loss of any currently available intervention. Ten-year follow-up data show that sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) both produce sustained excess weight loss in the range of 50–70%, with significant improvements in type 2 diabetes, hypertension, and obstructive sleep apnoea that go well beyond what diet, exercise, or pharmacotherapy achieves alone.
But outcomes vary — considerably. Patients who arrive at surgery nutritionally depleted, physically deconditioned, psychologically unprepared, or carrying a massively enlarged fatty liver face higher operative risk and poorer long-term results. The pre-operative period, which many patients treat as a waiting room, is actually a high-leverage intervention window. What you do in the weeks before surgery shapes what the surgeon finds on the table, how your body tolerates anaesthesia, and how sustainably you lose weight in the years that follow.
This guide covers the evidence on each component of pre-bariatric preparation as it applies in the Australian clinical context.
The sleeve is now the dominant bariatric procedure in Australia, accounting for approximately 75% of operations performed. The surgeon removes roughly 80% of the stomach, leaving a narrow tube or "sleeve." This restricts food intake volume and, importantly, eliminates most of the ghrelin-producing fundus, reducing appetite drive hormonally as well as mechanically. The sleeve does not reroute the intestine, which simplifies the operation and reduces some long-term malabsorption risks — though nutritional deficiencies still occur and require lifelong monitoring.
RYGB divides the stomach into a small upper pouch and bypasses a section of the small intestine. This produces both restriction and malabsorption. It is generally considered more effective for type 2 diabetes remission and produces somewhat greater weight loss than sleeve over the long term, but the altered anatomy creates greater risk of nutritional deficiency — particularly iron, B12, and calcium — and requires stricter lifelong supplementation.
The band has declined sharply in Australia over the past decade due to high long-term revision rates and comparatively modest weight loss outcomes. It involves placing an inflatable band around the upper stomach to create a small pouch. While reversible, it requires frequent adjustments and many patients eventually require conversion to sleeve or bypass. New band placements are now uncommon in Australian bariatric practice.
One of the most consistently underestimated components of bariatric preparation is the pre-operative liver diet. In patients with obesity, the liver — particularly the left lobe — is often substantially enlarged due to non-alcoholic fatty liver disease (NAFLD). An enlarged fatty liver sits directly over the stomach and makes laparoscopic access significantly more difficult, increasing operative time and risk of inadvertent liver laceration.
A two to four week very-low-calorie diet (VLCD) or low-carbohydrate diet before surgery has been shown to reduce liver volume by 15–20%, measurably improving surgical access and reducing operative complications. Most Australian bariatric centres use a structured protocol in this window, typically in the range of 800–1,200 kcal/day with high protein (at least 60–80 g/day) to spare lean muscle mass during the rapid reduction phase.
Many centres use total meal replacement programs such as Optifast for this period. These products are formulated to deliver adequate protein and micronutrients within a very low calorie ceiling, making compliance easier than attempting to construct a suitable whole-food diet at the same restriction level. Adherence to the liver shrinkage diet is also taken by surgical teams as a signal of the patient's capacity to follow post-operative dietary protocols — which are far more demanding and permanent.
Glycogen depletion from carbohydrate restriction is the primary mechanism: each gram of stored glycogen holds approximately 3–4 g of water, so low-carbohydrate diets rapidly reduce liver water and glycogen content before fat is substantially mobilised. The reduction in liver size is real and clinically meaningful within as little as two weeks.
Obesity is paradoxically a state of frequent micronutrient deficiency. Poor dietary quality, chronic low-grade inflammation, and impaired absorption all contribute. Bariatric surgery — particularly bypass procedures — then compounds these deficiencies by reducing stomach acid production, altering intestinal transit, and reducing food volume and variety. Arriving at surgery already deficient significantly worsens post-operative outcomes.
Pre-operative screening should include at minimum:
A baseline DEXA scan to assess lean mass is increasingly recommended at major bariatric centres. Given that rapid post-operative weight loss inevitably involves some lean tissue loss alongside fat, knowing the pre-operative baseline allows for more targeted protein and resistance exercise interventions to protect muscle through the weight loss phase. For more on this, see the strategies discussed in preserving muscle during rapid weight loss.
Cardiopulmonary fitness before surgery is a meaningful predictor of anaesthetic risk and post-operative complication rates. Patients with limited exercise capacity face higher risks of pulmonary complications, slower recovery, and longer hospital stays. This is particularly relevant in bariatric patients, who frequently have obstructive sleep apnoea, impaired respiratory mechanics from abdominal obesity, and reduced cardiovascular reserve.
A six-week supervised exercise program in the pre-operative period has been shown in randomised controlled trials to meaningfully reduce post-operative complication rates and improve recovery speed. Even modest targets matter: accumulating 150 minutes per week of moderate-intensity walking reduces operative risk, improves insulin sensitivity, and builds the movement habit that is central to long-term post-surgery success.
Resistance training in this window is also valuable. Preserving lean mass through the high-deficit post-operative phase is easier when muscle is better conditioned pre-operatively. For patients thinking about their longer-term trajectory, body recomposition post-surgery covers how to approach muscle preservation and rebuilding as weight stabilises.
Australian bariatric guidelines — including those from the Obesity Surgery Society of Australia and New Zealand (OSSANZ) — require psychological evaluation as part of the pre-operative workup. This is not a formality. Psychological factors are among the strongest predictors of long-term bariatric outcomes.
The assessment typically evaluates:
Patients identified as needing psychological support pre-operatively should engage with it genuinely, not just complete the process as a checkbox. Bariatric surgery changes the mechanics of eating permanently; the psychological adaptation required is substantial and best begun before the operation.
Patients who have been using GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) or liraglutide (Saxenda) — before pursuing bariatric surgery need to plan a pre-operative cessation period carefully. GLP-1 agonists significantly slow gastric emptying, which creates serious anaesthetic risk: delayed gastric emptying increases the likelihood of aspiration under general anaesthesia even with standard fasting protocols.
Most Australian bariatric anaesthetists now recommend cessation of weekly GLP-1 agonists (semaglutide) at least two to four weeks before surgery, with daily formulations (liraglutide) typically stopped one week prior. Extended protocols for patients on higher doses or with known severe gastroparesis may be longer. Discuss the specific timeline with your surgeon and anaesthetist — do not simply stop independently without clinical guidance.
For patients weighing pharmacological approaches before considering surgery, a comparison of GLP-1 medications before considering surgery covers the current options in the Australian context.
Other medications requiring review include NSAIDs (typically ceased pre-operatively and often contraindicated post-RYGB long-term), anticoagulants, diabetes medications where hypoglycaemia risk changes dramatically post-op, and hormonal contraceptives (absorption may be affected post-bypass). A full medication review with your GP and surgical team is essential.
The disparity between Australian public and private bariatric access is substantial and worth understanding clearly before committing to a pathway.
Public pathway: Bariatric surgery through major public hospital bariatric units — such as the Royal Melbourne, Westmead, Princess Alexandra, or Flinders Medical Centre programs — is available to eligible patients but involves significant wait times, commonly two to five years in most states. Eligibility criteria typically require a BMI above 40, or above 35 with significant comorbidities. The multidisciplinary care within these programs is often excellent, but the extended timeline means patients spend years in a holding pattern.
Private pathway: Private bariatric surgery with appropriate health insurance cover can be accessed within weeks to months. Total out-of-pocket costs depend heavily on the level of health insurance cover and the surgeon's fees. Typical estimates range from approximately $8,000 to $15,000 AUD for a sleeve gastrectomy with standard private hospital cover. Patients without insurance face much higher total costs. Choosing a surgeon with high case volume and accreditation through OSSANZ is important for outcome quality.
Medical tourism: Thailand and Mexico in particular market heavily to Australian bariatric patients, with all-inclusive packages often priced at $5,000–8,000 AUD. Outcomes at reputable overseas centres can be comparable, but complications management post-return, follow-up access, and the ability to navigate the Australian health system with overseas operative records all require careful consideration. Discuss this pathway thoroughly with your GP before committing.
Regardless of pathway, the pre-operative preparation work described in this article applies equally and can begin independently of where you are in the waiting or booking process.
Pre-bariatric preparation includes understanding and accepting the post-operative nutritional reality. Bariatric surgery is not a temporary intervention — and neither is the supplementation that follows it.
Following sleeve gastrectomy or bypass, lifelong supplementation is standard clinical practice:
Researchers exploring supportive nutritional and metabolic interventions alongside conventional bariatric care increasingly look at peptide and metabolic signalling pathways; those interested in the research direction can explore weight management peptide research for current developments in this area.
Regular blood work — typically at three months, six months, twelve months, and annually thereafter — is not optional. It is the mechanism by which deficiencies are caught before they cause clinical harm.
The weeks between committing to bariatric surgery and the operation date are not dead time. Every nutritional deficiency corrected, every kilogram of liver volume reduced, every fitness session completed, and every psychological pattern examined before surgery translates directly into reduced operative risk and better long-term outcomes.
Work with your bariatric dietitian and surgical team to build a specific pre-operative protocol suited to your procedure type and health status. The preparation phase is genuinely part of the treatment — and one of the few phases where you hold most of the variables.
Compounded semaglutide in Australia: why the TGA banned compounding in 2024, the safety concerns behind it, current legal status, and approved 2026 alternatives.
Liraglutide (Saxenda) and semaglutide (Wegovy) are both PBS-listed GLP-1 agonists approved for weight management in Australia. A detailed evidence comparison of efficacy, side effects, dosing, cost, and patient suitability.
A comprehensive guide to tirzepatide (Mounjaro) in Australia — covering TGA approval, PBS status, private prescription costs, SURMOUNT trial results, and how it compares to semaglutide for weight loss.